Drug Development Reviews|omicsgroup|Journal Of Clinical Toxicology

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Drug Development Reviews

Drug development can be defined as the process of developing a consumable drug or medicine from a lead compound. This is a highly extensive process starting form lead compound characterisation to precilinical trials and clinical trials and responses. “The biopharmaceutical industry has come a long way since the United States Food and Drug Administration (FDA) approval of the first biopharmaceutical (biologic) product insulin in 1982. In 2012, five of the top ten selling prescription drugs were biopharmaceuticals. Biopharmaceutical products have provided novel treatment modalities for life-threatening and rare diseases. In recent years, pharmaceutical companies are ramping up on their development of biosimilars because many patents on biological products are expiring and this enables them to earn profits from the biopharmaceutical market Biosimilars: The New Era of Drug Development? Drug development and related issues are one of the major areas of clinical toxicology research thus the journal always give priority to research in the field of drug development in various stages. During clinical trials and preclinical stages drugs may show lots and lots of adverse drug reactions and these up to date data needs to be revealed for improvising the drugs as well as reducing the reactions. Journal of Clinical Toxicology serves this purpose of highlighting the research in field of drug discovery and development.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on April, 2021